GSK plc Sponsored ADR (GSK)
GSK CEO on acquisition of biotech firm IDRx
Emma Walmsley, GSK CEO, joins 'Money Movers' to discuss the company's deal to acquire IDRx, the impact of Robert F. Kennedy Jr.'s administration position, and much more.
GSK swoops for US cancer specialist in $1.15bn deal
GSK PLC (LSE:GSK, NYSE:GSK) has announced plans to acquire the US biotech company IDRx for up to $1.15bn, including $1bn upfront, in a bid to expand its portfolio of cancer therapies. The deal includes IDRX-42, a promising drug designed to treat gastrointestinal stromal tumours (GIST), a rare and aggressive form of cancer that develops in the digestive tract.
GSK to buy US biotech firm IDRx for up to $1.15 billion
British drugmaker GSK said on Monday that it would pay up to $1.15 billion to buy Boston-based biopharmaceutical firm IDRx, which is developing a treatment for a rare type of tumour.
GSK's new shingles jab submitted for review by US regulator
GSK PLC (LSE:GSK, NYSE:GSK) has announced that the US Food and Drug Administration (FDA) is reviewing its new prefilled syringe version of Shingrix, its shingles vaccine. If approved, the updated delivery method would simplify vaccine administration by eliminating the need to mix separate components before use.
GSK swooping to buy US biotech IDRx for $1bn - report
UK pharma giant GSK PLC is close to buying US biotech startup IDRx for $1 billion to boost its cancer drug business, the Financial Times has reported. Backed by a raft of venture capital and private equity firms, the Plymouth, Massachusetts-based firm has been developing a treatment for gastrointestinal tumours.
GSK and Pfizer's RSV vaccines to carry warnings of neurological disorder risk
GSK and Pfizer's respiratory syncytial virus (RSV) vaccines will carry warnings that they can increase the risk of developing a rare neurological disorder, the U.S. Food Drug Administration said on Tuesday.
GSK's ADC Drug Gets FDA's Breakthrough Tag for Rare Bone Cancer
The FDA bestows a Breakthrough Therapy designation to GSK's antibody-drug conjugate, GSK5764227, for treating relapsed or refractory osteosarcoma.
GSK's experimental cancer drug wins receives support from US regulator
GSK PLC (LSE:GSK, NYSE:GSK) has received a major boost for its experimental drug GSK5764227 (GSK'227), which targets a rare and aggressive bone cancer called osteosarcoma. The US Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation to the treatment, which is being tested for patients whose cancer has returned after at least two prior treatments.
GSK's Nucala approved in China for treating nasal polyps
GSK PLC's (LSE:GSK, NYSE:GSK) Nucala (mepolizumab) has been approved in China to treat adults with chronic rhinosinusitis with nasal polyps (CRSwNP) when other therapies, like steroids or surgery, have not worked. This makes Nucala the first anti-interleukin-5 treatment available for this condition in China, where an estimated 30 million people live with CRSwNP.
GSK's FIRST trial achieves progression-free survival milestone in advanced ovarian cancer
GSK PLC (LSE:GSK, NYSE:GSK) has announced that its phase III FIRST-ENGOT-OV44 trial met its primary goal, or 'endpoint'. The study showed that the addition of Jemperli (dostarlimab) to platinum-based chemotherapy and Zejula (niraparib) maintenance, with or without bevacizumab, significantly improved progression-free survival (PFS) in first-line advanced ovarian cancer.
GSK's cancer drugs meet progression-free survival goal in late-stage trial
GSK said on Friday the addition of its cancer drug Jemperli to both standard of care chemotherapy and Zejula maintenance improved survival in patients with advanced ovarian cancer without the disease getting worse in a late-stage trial.
GSK Gets CHMP Nod for Expanded Use of HIV Combo & Jemperli
The CHMP recommends marketing approval to GSK's Vocabria plus JNJ's Rekambys for treating HIV-1 infection in adolescents aged 12 years and older.
